Verastem Inc (NASDAQ:VSTM)’s share price traded down 14% during trading on Monday . The stock traded as low as $3.12 and last traded at $3.14. 4,563,900 shares changed hands during trading, an increase of 459% from the average session volume of 816,673 shares. The stock had previously closed at $3.65.

Several equities analysts recently commented on the company. Cann restated a “buy” rating and set a $6.00 target price on shares of Verastem in a research report on Tuesday, November 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Verastem in a research report on Wednesday, November 8th. Oppenheimer restated a “buy” rating and set a $6.00 target price on shares of Verastem in a research report on Wednesday, September 6th. Roth Capital assumed coverage on Verastem in a research report on Friday, December 1st. They set a “buy” rating and a $12.00 target price for the company. Finally, Cantor Fitzgerald upgraded Verastem from a “neutral” rating to an “overweight” rating and set a $2.00 target price for the company in a research report on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $10.03.

The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.29). sell-side analysts anticipate that Verastem Inc will post -1.74 EPS for the current fiscal year.

In other news, Director Timothy J. Barberich acquired 60,538 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was purchased at an average cost of $3.95 per share, for a total transaction of $239,125.10. Following the acquisition, the director now owns 130,000 shares of the company’s stock, valued at $513,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.51% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new position in shares of Verastem in the 3rd quarter worth about $6,580,000. Vanguard Group Inc. boosted its holdings in shares of Verastem by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock worth $2,493,000 after purchasing an additional 107,029 shares in the last quarter. Artal Group S.A. boosted its holdings in shares of Verastem by 50.0% in the 3rd quarter. Artal Group S.A. now owns 750,000 shares of the biopharmaceutical company’s stock worth $3,525,000 after purchasing an additional 250,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Verastem by 93.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 561,969 shares of the biopharmaceutical company’s stock worth $2,641,000 after purchasing an additional 272,141 shares in the last quarter. Finally, EAM Investors LLC purchased a new position in shares of Verastem in the 3rd quarter worth about $2,092,000. Hedge funds and other institutional investors own 34.24% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Verastem (VSTM) Stock Price Down 14%” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/verastem-vstm-stock-price-down-14/1774157.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.